4820 Richard Road SW
225 articles with Resverlogix Corporation
Resverlogix Announces Presentations at Leading Scientific ConferencesPresentations on BET Inhibitor Apabetalone to be made during the American Society of Nephrology Kidney Week
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today its participation during the following leading scientific conferences: American Society of Nephrology (ASN) Kidney Week Reimagined 2020, 13 th Clinical Trials on Alzheimer's Disease (CTAD) digital event, and the American Heart Association (AHA) Scientific Sessions virtual experience, featuring OnDemand oral presentations on apabetalone. Through participation at le
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that Vision Leader Limited, a wholly-owned subsidiary of ORI Star Fund LP (“ORI”), has delivered a notice of conversion to convert its entire September 2019 debenture and associated interest, into Resverlogix common shares, which will discharge all security interests associated with the debenture. The US$12 million (approximately CAD$15.8 million) principal amount of the debe
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it has entered into a definitive stock purchase agreement for a private placement of 10,560,000 equity units at a price of $1.25 per unit for gross proceeds of $13.2 million (US$10 million). Each unit will be comprised of one common share and one common share purchase warrant. Each warrant will be exercisable at a price of $1.50 per share for a period of nine mo
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announces that, further to its September 25, 2020 press release , it today has filed its interim financial statements and related MD&A for the three months ended July 31, 2020 (the “Interim Filings”). These filings can be found at www.sedar.com under the Company’s profile . About Resverlogix Resverlogix is developing apabetalone (RVX-208), a first-in-class, small mole
Resverlogix Announces Publication in High-impact Peer-reviewed Journal – Medicinal Research ReviewsPublication Highlights the Therapeutic Potential of BET Inhibition across Multiple Human Diseases
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today the recent publication of an article titled: “ Inhibitors of bromodomain and extra ‐ terminal proteins for treating multiple human diseases” , in the peer-reviewed Medicinal Research Reviews. The publication can be viewed using the following LINK . “We assessed the current understanding of transcriptional mechanisms of BET inhibition to explain why BD2‐sel
Resverlogix Announces Participation at the Upcoming Global Chinese Financial Forum (“GCFF”) Virtual Conference 2020 – Investing in Innovation
Resverlogix Corp. announces its participation at the GCFF Virtual Conference 2020 - Investing in Innovation on September 10, 2020.
Resverlogix Announces Publication on Apabetalone in Cardiovascular TherapeuticsCOVID-19 Preclinical Work Continues
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce today the recent publication of an article titled: “ Epigenetic modulation by apabetalone counters cytokine driven acute phase response in vitro , in mice and in patients with cardiovascular disease” , in the peer-reviewed Cardiovascular Therapeutics. The publication can be viewed using the following LINK . “This publication highlights the cutting-edg
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announces that it intends to rely on blanket exemptions issued by provincial securities commissions due to the COVID-19 outbreak that permit the Company to extend the filing deadline of certain continuous disclosure documents for a period of up to 45 days. The Company intends to rely on the exemptive relief to extend the date of filing of its annual financial statements for the ye
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it has closed a one-year extension of the maturity date of its debenture. Mr. Donald McCaffrey, President and CEO stated, "We are very pleased that the debenture has been extended for one year, providing us with greater flexibility to create value for our shareholders through both our FDA approved BETonMACE2 final planning and our ongoing partnering discussions.
Resverlogix Corp. is pleased to announce that the U.S. Food & Drug Administration has accepted its BETonMACE2 clinical plan as a registration enabling study with positive implications for Resverlogix and its ongoing partnership discussions.
Resverlogix Announces Key BETonMACE Renal Data from Plenary Session Presentation at ERA-EDTA Virtual CongressMACE in the Chronic Kidney Disease group was reduced by 50%
Resverlogix Corp. is pleased to announce key data from its BETonMACE clinical trial in pre-specified stage 3 chronic kidney disease patients.
Resverlogix Plans COVID-19 Clinical Trial Program LaunchEpigenetic BET-inhibition to combat COVID-19
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce that it is moving forward with a plan to further evaluate apabetalone’s impact on COVID-19 in both a preclinical and clinical setting. A first step will be to investigate whether apabetalone treatment of human cells susceptible to 2019 novel coronavirus (2019-nCoV) infection will impact the replication cycle of the virus. Initial work – undertaken in an ap
Resverlogix Announces Participation at the American College of Cardiology Scientific Sessions together with the World Congress of Cardiology Virtual
Resverlogix Corp. announced its participation at the American College of Cardiology Scientific Sessions, together with the World Congress of Cardiology, presenting two virtual posters made available on demand via an eAbstracts System starting Saturday, March 28, 2020.
Resverlogix Announces Publication of Key Apabetalone Study BETonMACE in the Journal of the American Medical Association
Announces publication of accompanying JAMA editorial highlighting important secondary endpoints including congestive heart failure A pabetalone development program moving toward next study to enable a New Drug Application filing CALGARY, Alberta, March 30, 2020 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today the recent publication of an article titled: “ Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovas
Resverlogix Clinical Candidate Apabetalone Featured as a Potential COVID-19 Treatment in Recent PublicationEpigenetic BET-inhibition to combat COVID-19
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce a March 23, 2020 bioRxiv publication that has shown apabetalone to inhibit specialized proteins – called bromodomain and extraterminal domain (BET) proteins – from interacting with a SARS-CoV-2 viral protein, with potential for limiting viral reproduction in human cells. The article titled: “ A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Dr
Resverlogix Invites Collaborations for use of Apabetalone in Trials and Studies to Combat the Spread of COVID-19 Based on New Research
Recent findings point to BET protein and ACE2 inhibition as possible means to slow and reduce the impact of COVID-19
Resverlogix Confirms a Significant Corporate Advancement Establishing Apabetalone as a Potential Blockbuster Combination Drug in High-risk Diabetes Patients with CVD
BETonMACE Results Show 57% Hazard Reduction in Primary MACE for Patients on Apabetalone and New Oral Anti-Diabetic Treatments
Resverlogix Corp. reminds stakeholders that the Company will hold a conference call and webcast on December 6th at 8:30 am ET to supplement the presentation of prespecified BETonMACE cognition results to be disclosed at the Clinical Trials on Alzheimer's Disease Congress 2019.
Subsequent conference call & webcast scheduled to present BETonMACE prespecified cognition assessment results
Resverlogix Corp. announces a warrant exercise incentive program designed to encourage the early exercise of 15,593,428 warrants to purchase common shares of the Company.